Technical Analysis for GTBP - GT Biopharma, Inc.

Grade Last Price % Change Price Change
C 2.97 1.02% 0.03
GTBP closed up 1.02 percent on Friday, November 1, 2024, on 24 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Flat

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Calm After Storm Range Contraction 1.02%
NR7 Range Contraction 1.02%
Earnings Movers Other 1.02%

   Recent Intraday Alerts

Alert Time
Down 2 % about 21 hours ago
Up 2% about 21 hours ago
Possible NR7 about 21 hours ago
Possible Inside Day about 21 hours ago
60 Minute Opening Range Breakdown about 24 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GT Biopharma, Inc. Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors. Its central nervous system portfolio consists of GTP-004 for the treatment of myasthenia gravis, PainBrake to treat chronic neuropathic pain, and GTP-011 for the treatment of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Westlake Village, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Cancer Therapies Myasthenia Gravis Lectins Cd22 Siglec Treatment Of Myasthenia Gravis

Is GTBP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.6599
52 Week Low 1.9201
Average Volume 16,015
200-Day Moving Average 3.37
50-Day Moving Average 2.28
20-Day Moving Average 2.52
10-Day Moving Average 2.96
Average True Range 0.22
RSI (14) 64.54
ADX 43.85
+DI 40.39
-DI 11.88
Chandelier Exit (Long, 3 ATRs) 2.88
Chandelier Exit (Short, 3 ATRs) 2.62
Upper Bollinger Bands 3.49
Lower Bollinger Band 1.54
Percent B (%b) 0.73
BandWidth 77.67
MACD Line 0.26
MACD Signal Line 0.20
MACD Histogram 0.0588
Fundamentals Value
Market Cap 4.1 Million
Num Shares 1.38 Million
EPS -9.00
Price-to-Earnings (P/E) Ratio -0.33
Price-to-Sales 0.00
Price-to-Book 0.67
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.15
Resistance 3 (R3) 3.14 3.07 3.12
Resistance 2 (R2) 3.07 3.02 3.08 3.11
Resistance 1 (R1) 3.02 3.00 3.05 3.03 3.10
Pivot Point 2.95 2.95 2.96 2.96 2.95
Support 1 (S1) 2.90 2.90 2.93 2.91 2.84
Support 2 (S2) 2.83 2.88 2.84 2.83
Support 3 (S3) 2.78 2.83 2.82
Support 4 (S4) 2.79